Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer - Wikidata - wikimedia - TriplyDB

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

http://www.wikidata.org/entity/Q28247712

about

Trial watch - inhibiting PARP enzymes for anticancer therapy Advances in using PARP inhibitors to treat cancer Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent.Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma.Imaging the DNA damage response with PET and SPECT Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy.PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells.Radioiodinated PARP1 tracers for glioblastoma imaging.Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma.Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma PARP1 Inhibitors: antitumor drug design.Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene Immunoprofile from tissue microarrays to stratify familial breast cancer patients The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer.High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.Nicotinamide phosphoribosyltransferase in malignancy: a review.Correlation between PARP-1 immunoreactivity and cytomorphological features of parthanatos, a specific cellular death in breast cancer cells.PARP-1 may be involved in angiogenesis in epithelial ovarian cancer.Multispectral imaging: a review of its technical aspects and applications in anatomic pathology.PARP inhibitors Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.Critical protein GAPDH and its regulatory mechanisms in cancer cells.PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy.Let-7 Status Is Crucial for PARP1 Expression in HER2-Overexpressing Breast Tumors.Upregulated hPuf-A promotes breast cancer tumorigenesis.High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer.Nuclear PARP1 expression and its prognostic significance in breast cancer patients.

P2860

Q26745673-34972341-221E-4C14-84E5-96F95402C76B Q27003972-8C1386D4-8617-4D51-B8F1-07281F42437F Q27347956-08B0E56E-59EB-4443-B5BC-5DF9CE607663 Q30252194-7B5426BA-B629-4C70-9AA0-A95FCF559A4C Q33581909-1B5938A7-EA7C-4CBD-8CBC-C7C54400D4C4 Q33649555-E38B1272-D02F-4B41-99D4-63AEBCAFC39C Q34346449-8E9A1622-0D97-4962-97D1-420042EF0719 Q34493362-E02AAE21-AB3D-4B19-917A-1F0F65C5981B Q34502009-7C9E8DB8-3C4C-4230-B76E-60E1648D5562 Q34817460-294A8599-1F35-4346-A45F-E6C2FCFB6AC4 Q35146271-0525E992-7D1D-42AE-9F11-78F148047E42 Q35764111-F184CB66-E8EE-431B-B1A9-4305D4A48252 Q35903928-8C5BEF06-2B55-4CF5-B26C-1DF3FB77C474 Q35919277-F9C41E65-C097-4BC2-9CCB-A96F851CC062 Q36038008-07BEBB69-93C2-4D73-A83C-82AFDADEBB1E Q36137287-F6EB7EA3-2620-47FD-A063-79BB25B26328 Q36172457-8A60715F-70A1-403F-9B59-84AC7325868B Q36175159-FD71B4B7-8F60-4163-8147-1B7540341AE8 Q36284245-20CB4B5E-E660-4262-9A5D-9C1E080BC82C Q36377960-642661EE-D762-4043-A74E-CCBB07F76E74 Q36413813-F9B4761C-A333-4844-80A5-7E81BBB6DDCF Q36413928-AFD66871-9814-40A2-A2EE-3096D1F1A26C Q36500327-8F80891A-F765-42AF-B1F7-A87D47CEE7B2 Q36537404-73DADF49-BB34-4435-99DB-AAE2A548E3E5 Q36558409-7A51B4EB-8FBB-4251-A305-4998AFE77268 Q36689103-AAF24B62-6A6E-47BF-9C31-0F16BC47FAE1 Q36768822-CBE9777E-8D2A-46E6-82FF-6B777D6EAAB9 Q36827491-92325275-A063-47D9-8519-0069ABCC7B96 Q37424391-ACE70756-F9EC-428E-9B8C-D85DA516C420 Q37494636-4648D388-6EC9-4C54-B37F-912A8BDDD8B9 Q37581637-3AC7DA46-7C0A-4A3C-8B5B-A77AD4E1D98E Q38152999-9140E75E-D149-40DD-8D1B-CA73D4907C55 Q38326336-CD3C4DA6-6258-485A-A702-A85D849C72DD Q38377713-582BA26C-FE22-4524-8863-0AC795E76EF5 Q38413973-9F09F1C2-B13A-44F7-8F96-4D7B7D0F961B Q38719698-1178F1EE-B90B-4AA8-AFDF-19AAB3C79C4F Q38723917-4EA85DFE-A962-44D1-BADB-F362942E3E3F Q39159051-01FB1848-5A0F-49B0-9298-99F24E3F9DF1 Q40432109-D87D6CBB-7F8E-44E6-BA81-8ECAA7950572 Q41091405-C2D49912-FFDA-4822-B260-6D00DB4E0FDA

P2860

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

http://www.wikidata.org/entity/Q28247712

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Nuclear PARP-1 protein overexp ...... urvival in early breast cancer

@ast

Nuclear PARP-1 protein overexp ...... urvival in early breast cancer

@en

Nuclear PARP-1 protein overexp ...... urvival in early breast cancer

@nl

type

label

Nuclear PARP-1 protein overexp ...... urvival in early breast cancer

@ast

Nuclear PARP-1 protein overexp ...... urvival in early breast cancer

@en

Nuclear PARP-1 protein overexp ...... urvival in early breast cancer

@nl

prefLabel

Nuclear PARP-1 protein overexp ...... urvival in early breast cancer

@ast

Nuclear PARP-1 protein overexp ...... urvival in early breast cancer

@en

Nuclear PARP-1 protein overexp ...... urvival in early breast cancer

@nl

P1433

Q28247712-75A5EAF0-01E4-4B11-9435-FB6F4F670947

P1476

Q28247712-6C6D0EB5-B132-4893-B61A-7A9991D4F675

P2093

Q28247712-02727ACE-B77B-47C5-9609-00D9B3CC934B

Q28247712-0C2FA70D-9D5A-423C-99AE-C1F1F2ED2280

Q28247712-0DABAC17-BBDC-4E0B-938B-8487BBD8ABFB

Q28247712-1097AEB8-4E7F-43CF-9564-9194608C2831

Q28247712-114F98AD-D5BA-4662-8015-4FD9E1823F02

Q28247712-161E4618-1FE4-4852-9042-37FBA9E0B093

Q28247712-1876C5D1-7B7C-4251-85CB-5E5492842EA4

Q28247712-2C9A1D30-26C3-4C01-99C8-449328FB77D5

Q28247712-3582DA70-3C04-4058-93E4-029AEA02C6AC

Q28247712-53790292-5869-4735-BDE1-DAADA9129448

P2860

Q28247712-027C2D2C-54F9-4E25-B6C3-F6D13D3BD3BA

Q28247712-067A0D36-1A2F-4C39-BCEF-75F37FE6824C

Q28247712-0E523D69-42D8-41E9-918E-4C5CE2CE225F

Q28247712-24118644-17A8-4C06-921A-9B3FD6E158DB

Q28247712-2FA14C40-5552-47B3-9119-63A679CEBD61

Q28247712-366C3A25-D4BF-422C-9BCF-63BE358D4B52

Q28247712-3683A2E1-EF62-4B82-B7A2-12487C61FF8E

Q28247712-46B77250-2532-4D9D-A3A4-83F15A4BF8FA

Q28247712-4A97B658-FB15-4A86-8CB9-CDD0D81E577B

Q28247712-4AF83928-C46C-423F-A319-73617BD840D6

P304

Q28247712-9D20CB6A-B7D9-4765-B5B0-3322CFE9414B

P31

Q28247712-18A22702-8162-4E06-85C8-81C70AE00CC7

P3181

Q28247712-6E16BC05-0227-4714-8A1D-EBF02A80C242

P356

Q28247712-1D54690F-C642-4AB8-B782-563F0C4EA83B

P407

Q28247712-36DF0293-E6CA-4068-8616-9BE677C9207B

P433

Q28247712-D46C7066-2BF8-4ABD-B40A-417A34A2D081

P478

Q28247712-36C05925-6C7C-4A31-8EFB-FD1C12DAA939

P577

Q28247712-71FDA52A-F636-4E8C-8029-492527F73FF9

P5875

Q28247712-366814E7-4E8B-4C0F-8147-83263D629881

P698

Q28247712-496BDA3A-9AE8-4B97-B908-9DAF82EB18AF

P921

Q28247712-06BCCA7A-A693-46E2-B159-023C84720F1C

P3181

P356

P1433

Annals of Oncology

P1476

Nuclear PARP-1 protein overexp ...... urvival in early breast cancer

@en

P2093

A Lluch

http://www.w3.org/2001/XMLSchema#string

A Rovira

http://www.w3.org/2001/XMLSchema#string

B Bellosillo

http://www.w3.org/2001/XMLSchema#string

C Chamizo

http://www.w3.org/2001/XMLSchema#string

F Lobo

http://www.w3.org/2001/XMLSchema#string

F Rojo

http://www.w3.org/2001/XMLSchema#string

I Tusquets

http://www.w3.org/2001/XMLSchema#string

J Albanell

http://www.w3.org/2001/XMLSchema#string

J Ferrer-Lozano

http://www.w3.org/2001/XMLSchema#string

J García-Parra

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Poly(ADP-ribose): novel functions for an old molecule

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors

P304

1156-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2484531

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/ANNONC/MDR361

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51639947

http://www.w3.org/2001/XMLSchema#string

P698

21908496

http://www.w3.org/2001/XMLSchema#string

P921